Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that involves synovial tissue and leads to joint destruction. There are currently 5 tumor necrosis factor (TNF) antagonists licensed for the treatment of RA. This review summarizes the predictors of response to TNF antagonists in RA. Demographic variables were found to predict response, although not consistently. The variables associated with poor clinical response were presence of radiographic joint erosions at baseline, poor functional capacity at baseline, presence of human antibodies against TNF chimeric antibodies, and increase in anti-DNA and antinuclear antibodies. In selected populations, polymorphisms of TNF, TNF receptor, and Fc γ receptor were related to clinical response. Expression of TNF and other inflammatory cytokines in synovial tissue was explored. The heterogeneity of study populations limits the generalizability of the results in most studies.
Keywords: Rheumatoid arthritis, response, biomarkers, TNF antagonists.
Current Pharmaceutical Design
Title:Predictors of Response to TNF Antagonists
Volume: 21 Issue: 2
Author(s): Eva Salgado, Jose Ramon Maneiro and Juan J. Gomez-Reino
Affiliation:
Keywords: Rheumatoid arthritis, response, biomarkers, TNF antagonists.
Abstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease that involves synovial tissue and leads to joint destruction. There are currently 5 tumor necrosis factor (TNF) antagonists licensed for the treatment of RA. This review summarizes the predictors of response to TNF antagonists in RA. Demographic variables were found to predict response, although not consistently. The variables associated with poor clinical response were presence of radiographic joint erosions at baseline, poor functional capacity at baseline, presence of human antibodies against TNF chimeric antibodies, and increase in anti-DNA and antinuclear antibodies. In selected populations, polymorphisms of TNF, TNF receptor, and Fc γ receptor were related to clinical response. Expression of TNF and other inflammatory cytokines in synovial tissue was explored. The heterogeneity of study populations limits the generalizability of the results in most studies.
Export Options
About this article
Cite this article as:
Salgado Eva, Ramon Maneiro Jose and Gomez-Reino Juan J., Predictors of Response to TNF Antagonists, Current Pharmaceutical Design 2015; 21 (2) . https://dx.doi.org/10.2174/1381612820666140825124152
DOI https://dx.doi.org/10.2174/1381612820666140825124152 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
VEGF, Angiopoietin-1 and -2 in Bronchial Asthma: New Molecular Targets in Airway Angiogenesis and Microvascular Remodeling
Recent Patents on Inflammation & Allergy Drug Discovery Assessment and Management of Loose Bodies in the Knee Joint and Related Disease: A Narrative Review
Current Rheumatology Reviews A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued) Anti-arthritic Effect and Underlying Mechanism of Ginsenoside Metabolite Compound K
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Osteoprotegerin A Physiological and Pharmacological Inhibitor of Bone Resorption.
Current Pharmaceutical Design The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands
Current Cardiology Reviews Exercise and Cognitive-Behavioural Treatment in Fibromyalgia Syndrome
Current Pharmaceutical Design Stimuli-responsive Drug Delivery Systems as an Emerging Platform for Treatment of Rheumatoid Arthritis
Current Pharmaceutical Design Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Systemic Autoimmune Manifestations: When Should Underlying Thyroid Autoimmunity be Considered?
Current Rheumatology Reviews Paracetamol (Acetaminophen) Efficacy and Safety in the Newborn
Current Drug Metabolism Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Curcumin has Bright Prospects for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions
Current Medicinal Chemistry Targeted Cancer Immunotherapy Using Ligands of the Tumor Necrosis Factor Super-Family
Current Drug Targets Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Periodontal Diseases and Rheumatoid Arthritis: A Coincident Model for Therapeutic Intervention?
Current Drug Metabolism Natural and Induced Antibody Polyreactivity
Anti-Cancer Agents in Medicinal Chemistry